DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo


company name or ticker

Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan

UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog

Valeant Pharmaceuticals Downplays Strategy Shift News

Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO

Where Could ValueAct Capital's New $1.5 Billion Go?

Will Valeant Pharmaceuticals (VRX) Stock be Helped Today by New Strategy?

Novartis (NVS) Presents Additional Data on Leukemia Drug - Analyst Blog

This Could Be the Next Big Pharma Buyout

Three Motley Fool analysts tell investors which three companies they think would be ripe for an acquisition.

Is It Time to Buy This Growth Stock?

Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?

The 3 Most Memorable Moments in Healthcare This Year

Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.
See More Articles...